Application 207145

Type: NDA
Sponsor: US WORLDMEDS LLC

Application Products#

Product, Drug, Ingredient table
Product	Drug	Ingredient	Form	Strength	Reference drug	Reference standard
001	XADAGO	SAFINAMIDE MESYLATE	TABLET;ORAL	50MG	Yes	No
002	XADAGO	SAFINAMIDE MESYLATE	TABLET;ORAL	100MG	Yes	Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N207145-001	XADAGO	SAFINAMIDE MESYLATE	EQ 50MG BASE	TABLET / ORAL	AB	RLD	2017-03-21
N207145-002	XADAGO	SAFINAMIDE MESYLATE	EQ 100MG BASE	TABLET / ORAL	AB	RLD, RS	2017-03-21

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-product	TE code
N207145-001	AB
N207145-002	AB

Orange Book patents#

Current patent rows page 1 of 1 · 6 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20
N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20
N207145-001	8283380	2031-03-21	U-1993		2017-04-20
N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20
N207145-002	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20
N207145-002	8283380	2031-03-21	U-1993		2017-04-20

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 3 of 3 · 88 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	RLD / RS	Approval date	Source SHA-256
2022-10-28 04:53 UTC	2022-10	N207145-001	XADAGO	EQ 50MG BASE	TABLET / ORAL		RLD	2017-03-21	`f41ea6bd6efb…`
2022-10-28 04:53 UTC	2022-10	N207145-002	XADAGO	EQ 100MG BASE	TABLET / ORAL		RLD, RS	2017-03-21	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	N207145-001	XADAGO	EQ 50MG BASE	TABLET / ORAL		RLD	2017-03-21	`e64feba35796…`
2022-09-29 23:25 UTC	2022-09	N207145-002	XADAGO	EQ 100MG BASE	TABLET / ORAL		RLD, RS	2017-03-21	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N207145-001	XADAGO	EQ 50MG BASE	TABLET / ORAL		RLD	2017-03-21	`cb3db0bc1861…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N207145-002	XADAGO	EQ 100MG BASE	TABLET / ORAL		RLD, RS	2017-03-21	`cb3db0bc1861…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207145-001	XADAGO	EQ 50MG BASE	TABLET / ORAL	AB	RLD	2017-03-21	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207145-002	XADAGO	EQ 100MG BASE	TABLET / ORAL	AB	RLD, RS	2017-03-21	`a50c72e98297…`

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-10-15 13:18:30	2026-09	N207145-001	AB	1	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N207145-002	AB	1	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N207145-001	AB	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207145-002	AB	1	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N207145-001	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207145-002	AB	1	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N207145-001	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207145-002	AB	1	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-001	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-002	AB	1	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N207145-001	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207145-002	AB	1	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207145-001	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207145-002	AB	1	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N207145-001	AB	1	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N207145-002	AB	1	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N207145-001	AB	1	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N207145-002	AB	1	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N207145-001	AB	1	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N207145-002	AB	1	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N207145-001	AB	1	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N207145-002	AB	1	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N207145-001	AB	1	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N207145-002	AB	1	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N207145-001	AB	1	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N207145-002	AB	1	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N207145-001	AB	1	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N207145-002	AB	1	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N207145-001	AB	1	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N207145-002	AB	1	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N207145-001	AB	1	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N207145-002	AB	1	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N207145-001	AB	1	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N207145-002	AB	1	`8072bd15b7f6…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207145-001	AB	1	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N207145-002	AB	1	`a50c72e98297…`

Observed Orange Book patent history#

Patent history page 1 of 7 · 264 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-10-15 13:18:30	2026-09	N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N207145-001	8283380	2031-03-21	U-1993		2017-04-20	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N207145-002	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N207145-002	8283380	2031-03-21	U-1993		2017-04-20	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207145-001	8283380	2031-03-21	U-1993		2017-04-20	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207145-002	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207145-002	8283380	2031-03-21	U-1993		2017-04-20	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207145-001	8283380	2031-03-21	U-1993		2017-04-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207145-002	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207145-002	8283380	2031-03-21	U-1993		2017-04-20	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207145-001	8283380	2031-03-21	U-1993		2017-04-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207145-002	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207145-002	8283380	2031-03-21	U-1993		2017-04-20	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-001	8283380	2031-03-21	U-1993		2017-04-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-002	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207145-002	8283380	2031-03-21	U-1993		2017-04-20	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207145-001	8283380	2031-03-21	U-1993		2017-04-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207145-002	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207145-002	8283380	2031-03-21	U-1993		2017-04-20	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207145-001	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207145-001	8076515	2028-12-10	U-1993	Drug substance, Drug product	2017-04-20	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207145-001	8283380	2031-03-21	U-1993		2017-04-20	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207145-002	8278485	2027-06-08	U-1993	Drug substance	2017-04-20	`fd3edfee7708…`

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207145-001	NCE	2022-03-21	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207145-002	NCE	2022-03-21	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N207145-001	NCE	2022-03-21	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N207145-002	NCE	2022-03-21	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N207145-001	NCE	2022-03-21	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N207145-002	NCE	2022-03-21	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N207145-001	NCE	2022-03-21	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N207145-002	NCE	2022-03-21	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N207145-001	NCE	2022-03-21	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	N207145-002	NCE	2022-03-21	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N207145-001	NCE	2022-03-21	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N207145-002	NCE	2022-03-21	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N207145-001	NCE	2022-03-21	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N207145-002	NCE	2022-03-21	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N207145-001	NCE	2022-03-21	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	N207145-002	NCE	2022-03-21	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N207145-001	NCE	2022-03-21	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N207145-002	NCE	2022-03-21	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N207145-001	NCE	2022-03-21	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N207145-002	NCE	2022-03-21	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N207145-001	NCE	2022-03-21	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N207145-002	NCE	2022-03-21	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N207145-001	NCE	2022-03-21	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N207145-002	NCE	2022-03-21	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N207145-001	NCE	2022-03-21	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N207145-002	NCE	2022-03-21	`ea99ee380514…`
2023-01-26 05:58 UTC	2023-01	N207145-001	NCE	2022-03-21	`3bdfa0b2c4d7…`
2023-01-26 05:58 UTC	2023-01	N207145-002	NCE	2022-03-21	`3bdfa0b2c4d7…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N207145-001	NCE	2022-03-21	`3a93d1ddd44b…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N207145-002	NCE	2022-03-21	`3a93d1ddd44b…`
2022-10-28 04:53 UTC	2022-10	N207145-001	NCE	2022-03-21	`f41ea6bd6efb…`
2022-10-28 04:53 UTC	2022-10	N207145-002	NCE	2022-03-21	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	N207145-001	NCE	2022-03-21	`e64feba35796…`
2022-09-29 23:25 UTC	2022-09	N207145-002	NCE	2022-03-21	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N207145-001	NCE	2022-03-21	`cb3db0bc1861…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N207145-002	NCE	2022-03-21	`cb3db0bc1861…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 18 matching rows.

NDC, Name, Nonproprietary name table
NDC	Name	Nonproprietary name	Labeler	Marketing category	Status
27505-110	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current
27505-110	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current
27505-110	Xadago	safinamide mesylate	MDD US Operations, LLC	NDA	Current
27505-110	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current
27505-110	Xadago	safinamide mesylate	MDD US Operations, LLC	NDA	Current
27505-110	Xadago	safinamide mesylate	MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.	NDA	Current
27505-110	Xadago	safinamide mesylate	MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.	NDA	Current
27505-110	Xadago	safinamide mesylate	MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.	NDA	Current
27505-110	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current
27505-111	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current
27505-111	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current
27505-111	Xadago	safinamide mesylate	MDD US Operations, LLC	NDA	Current
27505-111	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current
27505-111	Xadago	safinamide mesylate	MDD US Operations, LLC	NDA	Current
27505-111	Xadago	safinamide mesylate	MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.	NDA	Current
27505-111	Xadago	safinamide mesylate	MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.	NDA	Current
27505-111	Xadago	safinamide mesylate	MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.	NDA	Current
27505-111	Xadago	safinamide mesylate	US WorldMeds, LLC	NDA	Current

Documents#

Document, Submission type, Date table
Document	Submission type	Date
68325	SUPPL	2021-08-10
68316	SUPPL	2021-08-09
61100	SUPPL	2019-11-29
61081	SUPPL	2019-11-27
48775	SUPPL	2017-06-20
48756	SUPPL	2017-06-19
48180	ORIG	2017-05-01
47730	ORIG	2017-03-28
47630	ORIG	2017-03-22